Presidio Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Presidio Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7598
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Presidio Pharmaceuticals Inc (Presidio Pharmaceuticals) is a clinical-stage pharmaceutical company that discovers, develops, and supplies small-molecule antiviral therapeutics. The company’s products include HCV NS5A, protease inhibitor, ravidasvir hydrochloride, NS5B proteins, lead pan-genotypic HCV NS5A inhibitor, faldaprevir and non-nucleoside inhibitor. Its lead pan-genotypic HCV NS5A inhibitor, ravidasvir hydrochloride has completed phase 1 clinical studies in both healthy volunteers and HCV patients. Presidio Pharmaceuticals’ second pan-genotypic HCV inhibitor PPI-383 is a NS5B non-nucleoside inhibitor currently being evaluated in phase 1 studies. The company also has an extensive intellectual property portfolio for its HCV programs. Presidio Pharmaceuticals is headquartered in San Francisco, California, the US.

Presidio Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Presidio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Presidio Pharma Raises Additional USD13 Million in Series D Venture Financing 11
Presidio Pharma Raises US$8.6 Million In Series D Financing 12
Presidio Pharma Raises Additional US$8 Million In Series C Financing 13
Private Equity 14
Sobera Capital Acquires Equity Holdings in 12 Pharma Companies 14
Licensing Agreements 16
Pharco Pharma Enters into Licensing Agreement with Presidio Pharma for PPI-668 16
Ascletis Enters into Licensing Agreement with Presidio Pharma for PPI-668 17
Presidio Pharmaceuticals Inc – Key Competitors 18
Presidio Pharmaceuticals Inc – Key Employees 19
Presidio Pharmaceuticals Inc – Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Presidio Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Presidio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Presidio Pharma Raises Additional USD13 Million in Series D Venture Financing 11
Presidio Pharma Raises US$8.6 Million In Series D Financing 12
Presidio Pharma Raises Additional US$8 Million In Series C Financing 13
Sobera Capital Acquires Equity Holdings in 12 Pharma Companies 14
Pharco Pharma Enters into Licensing Agreement with Presidio Pharma for PPI-668 16
Ascletis Enters into Licensing Agreement with Presidio Pharma for PPI-668 17
Presidio Pharmaceuticals Inc, Key Competitors 18
Presidio Pharmaceuticals Inc, Key Employees 19

List of Figures
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Presidio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Presidio Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Qaf Limited:企業の戦略・SWOT・財務分析
    Qaf Limited - Strategy, SWOT and Corporate Finance Report Summary Qaf Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Nucor Corporation:企業のM&A・事業提携・投資動向
    Nucor Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Nucor Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Erste Group Bank AG:企業の戦略・SWOT・財務分析
    Erste Group Bank AG - Strategy, SWOT and Corporate Finance Report Summary Erste Group Bank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Brokk AB:企業の戦略的SWOT分析
    Brokk AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Banco Santander (Brasil) SA:企業のM&A・事業提携・投資動向
    Banco Santander (Brasil) SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Banco Santander (Brasil) SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Encavis AG (CAP):企業の財務・戦略的SWOT分析
    Summary Encavis AG (Encavis), formally Capital Stage AG, is an independent power producer. It offer investment services such as asset sourcing, due diligence, management, and documentation of renewable energy assets. Encavis also provides technical services comprising monitoring, reporting, fault ma …
  • Lundin Gold Inc:企業の戦略・SWOT・財務情報
    Lundin Gold Inc - Strategy, SWOT and Corporate Finance Report Summary Lundin Gold Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Avraham Pharmaceuticals Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Avraham Pharmaceuticals Ltd (Avraham Pharmaceuticals) is a pharmaceutical company that develops novel products for treatment and prevention of neurodegenerative disorders. The company offers a product, Ladostigil. It offers product in the therapeutic area of mild cognitive impairment. Avraha …
  • Immco Diagnostics Inc-製薬・医療分野:企業M&A・提携分析
    Summary IMMCO Diagnostics Inc (IMMCO), a subsidiary of Trinity Biotech Plc is a biotechnology company that offers autoimmune disease diagnostic solutions. The company offers a wide range of IFAs, EIAs, Line Immunoassays and Western Blots for an extensive variety of autoimmune disorders. It also deve …
  • Hooker Furniture Corp (HOFT):企業の財務・戦略的SWOT分析
    Hooker Furniture Corp (HOFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Havells India Ltd (HAVELLS):企業の財務・戦略的SWOT分析
    Havells India Ltd (HAVELLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Guerbet SA (GBT)-医療機器分野:企業M&A・提携分析
    Summary Guerbet SA (Guerbet) is a specialty pharmaceutical company which manufactures and markets medical imaging contrast agents destined for diagnostic purposes. The company provides a wide range of contrast agents for X-ray examinations and Magnetic Resonance Imaging (MRI). Guerbet also provides …
  • Dentsu Inc (4324):企業の財務・戦略的SWOT分析
    Dentsu Inc (4324) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Intellia Therapeutics Inc (NTLA):企業の財務・戦略的SWOT分析
    Summary Intellia Therapeutics Inc (Intellia Therapeutics) is a genome editing company. It develops proprietary curative therapeutics using CRISPR/Cas9 technology. The company develops in vivo programs for the treatment of liver diseases such as alpha-1 antitrypsin deficiency, and primary hyperoxalur …
  • Sun Life Hong Kong Limited:企業の戦略・SWOT・財務分析
    Sun Life Hong Kong Limited - Strategy, SWOT and Corporate Finance Report Summary Sun Life Hong Kong Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • j2 Global, Inc.:企業のM&A・事業提携・投資動向
    j2 Global, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's j2 Global, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Bankinter Banca Privada:企業の戦略・SWOT・財務分析
    Bankinter Banca Privada - Strategy, SWOT and Corporate Finance Report Summary Bankinter Banca Privada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • SDIX LLC:医療機器:M&Aディール及び事業提携情報
    Summary SDIX LLC (SDIX), a subsidiary of OriGene Technologies Inc, is an immuno-solutions company that develops antibody-based solutions. The company provides IVD solutions and premade antibiotics, among others. Its IVD solutions provide co-development of analyte-specific reagents, diagnostic menu e …
  • Central Iowa Power Cooperative:企業の戦略的SWOT分析
    Central Iowa Power Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Eni SpA (ENI):企業の財務・戦略的SWOT分析
    Eni SpA (ENI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆